Last checked at 
LONDON (Alliance News) - Neuroscience technology firm Cambridge Cognition Holdings PLC on Thursday said its NeuroVocalix platform is ready for clinical trials.
NeuroVocalix, the company said, allows voice-based cognitive assessments to be sent directly to patients through mobile and tele-health platforms.
This, it continued, improves the outcome of clinical trials, and also helps decision making during these trials.
One of the main focuses for NeuroVocalix will be for chronic pain, with the technology designed to elicit and automatically analyse pain-related signals in the human voice, Cambridge Cognition said.
Chief Executive Steven Powell commented: "This new platform is a key step in the company's strategy for growth; developing innovative near-patient digital technologies to optimise drug development and patient health outcomes.
"Voice biomarker data provides our commercial partners with additional insights into drug treatment outcomes and compliments our mobile, wearable and web-based digital health technologies in assessing cognition and brain health anytime, anywhere."
Shares were 1.2% higher on Thursday at a price of 132.00 pence each.